UPDATE Montefiore/Einstein Lead Drug Trial on COVID-19 Merck Antiviral Drug, Approved in the UK
As part of a recently launched international phase 3 clinical trial, officials at Montefiore Health System and the Albert Einstein College of Medicine announced on Monday, Nov. 8, that they are jointly investigating whether the Merck antiviral pill, molnupiravir, approved last week in Britain for treating COVID-19, can prevent COVID-19 in unvaccinated individuals living with people who have contracted the disease. Montefiore-Einstein is the first and only New York State site for such a trial, according to officials. U.S. drug company, Merck, recently announced that people with mild or moderate cases of COVID-19 who took molnupiravir reduced their
